To assess the prevalence and associated risk factors for human immunodeficiency virus (HIV) infection in patients attending inner-city clinics for sexually transmitted diseases in Baltimore, we screened 4028 patients anonymously, of whom 209 (5.2 percent) were seropositive for HIV. HIV-seropositivity rates were higher among men (6.3 percent) than women (3.0 percent) (P less than 0.001) and among blacks (5.0 percent) than whites (1.2 percent) (P less than 0.02). Among men, but not women, HIV seroprevalence increased markedly and steadily up to the age of 40. In men, HIV seropositivity was independently associated with increased age, black race, a history of homosexual contact, and the use of parenteral drugs. In women, a history of parenteral drug use or of being a sexual partner of a bisexual man or parenteral drug user were independently predictive of HIV seropositivity. In men, HIV seropositivity was also associated with a history of syphilis or a reactive serologic test for syphilis, and in women, with a history of genital warts. Since these associations were independent of the type and number of reported sexual partners, they raise the possibility that sexually transmitted diseases that disrupt epithelial surfaces may be important in the transmissibility of HIV. In addition, on a self-administered questionnaire, one third of HIV-infected men and one half of infected women did not acknowledge previous high-risk behavior for HIV exposure. These data suggest that patients at clinics for sexually transmitted diseases represent a group at high risk for HIV infection, and that screening, counseling, and intensive education should be offered to all patients attending such clinics.
The Neonatal Behavioral Assessment Scale was administered to a group of premature infants both prior to and following a nursery program of enriched tactile stimulation. The same instrument was administered twice to a control group of prematures who received no intervening "extra" stimulation. Whereas control infants showed changes of 2 or more points on only 2 of the instrument's 26 scales, the experimental babies showed positive changes of 2 or more points on 11 scales. There were no difference in weight gain between the two groups.
BackgroundExposure to the dinoflagellate Pfiesteria has, under certain circumstances, been associated with deficits in human
learning and memory. However, uncertainties remain about the health
risk of chronic, low-level exposures (as seen among occupationally exposed
commercial fishermen), particularly in light of studies suggesting
that Pfiesteria strains are widespread in the estuarine environment in the U.S. mid-Atlantic
region.MethodsWe selected an initial cohort of 152 persons, including 123 persons with
regular, occupational exposure to the Chesapeake Bay; 107 of the cohort
members were followed for the full four summer “seasons” of
the study. Cohort members were questioned biweekly about symptoms, and
data were collected about the areas of the bay in which they
worked. These latter data were matched with data on the presence or
absence of Pfiesteria in each area, based on polymerase chain reaction analysis of > 3,500 water
samples. Cohort members underwent neuropsychological testing at
the beginning and end of each summer season.ResultsNo correlation was found between work in an area where Pfiesteria was identified and specific symptomatology or changes on neuropsychological
tests.ConclusionsAlthough high-level or outbreak-associated exposure to Pfiesteria species (or specific strains within a species) may have an effect on health, routine
occupational exposure to estuarine environments in which
these organisms are present does not appear to pose a significant health
risk.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.